Integra LifeSciences Holdings Corporation (IART) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Integra LifeSciences Holdings Corporation (IART:NASDAQ), powered by AI.

Current Price
$9.53
P/E Ratio
-105.9
Market Cap
735M
Sector
Healthcare
What is the Integra LifeSciences Holdings Corporation stock price forecast?

Integra LifeSciences Holdings Corporation is currently trading at $9.53. View real-time AI analysis on Alpha Lenz.

What is Integra LifeSciences Holdings Corporation insider trading activity?

View the latest insider trading data for Integra LifeSciences Holdings Corporation on Alpha Lenz.

What is Integra LifeSciences Holdings Corporation's P/E ratio?

Integra LifeSciences Holdings Corporation's P/E ratio is -105.9.

Integra LifeSciences Holdings Corporation

$9.53
NASDAQIART
Ask about Integra LifeSciences Holdings Corporation's future dividend policy...
Alpha Chat Insight

Integra LifeSciences Holdings Corporation trades at a P/E of -105.9 (undervalued) with modest ROE of -0.4%.

Ask for details

Company Overview

Integra LifeSciences Holdings Corporation is a prominent company in the medical device field, focused on providing innovative solutions for patients and healthcare professionals globally. Known for its comprehensive portfolio, Integra LifeSciences develops, manufactures, and markets medical devices used primarily in neurosurgery, reconstructive surgery, and regenerative medicine. The company's offerings include a variety of implants, devices, and instruments designed to improve surgical procedures and outcomes. Integra LifeSciences serves multiple sectors within the healthcare industry, including hospitals, surgical centers, and rehabilitation facilities. The organization's commitment to advancing medical technology positions it as a critical player in enhancing patient care and driving medical advancements. Founded in 1989, Integra LifeSciences has established a significant presence in both domestic and international markets, continually striving to innovate and improve the quality of life for patients worldwide. Its role in the healthcare sector underscores the importance of technological development in medical applications, impacting numerous lives through its research and development efforts.

CEOMs. Mojdeh Poul
SectorHealthcare
IndustryMedical Devices
Employees4,396

Company Statistics

(FY 2024)

Profile

Market Cap$735.37M
Revenue$1.61B
Shares Out0.00
Employees4,396

Margins

Gross54.77%
EBITDA12.00%
Operating1.76%
Pre-Tax-1.13%
Net-0.43%

Valuation

P/E-105.90
P/B0.48
EV/Sales0.46
EV/EBITDA12.80
P/FCF48.99

Growth (CAGR)

Rev 3Yr1.45%
Rev 5Yr1.20%
Op Inc 3Yr-47.58%
Op Inc 5Yr-29.11%
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-0.18%
ROE-0.44%
ROIC1.34%

Financial Health

Cash & Cash Equivalents$246.38M
Net Debt$2.25B
Debt/Equity161.27%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Integra LifeSciences Holdings Corporation (Healthcare) Stock Forecast & Analysis $9.53 | Alpha Lenz